WuXi AppTec Sells China Clinical Research Business to Sharpen Focus

WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life science industries, and Hillhouse, a global private alternative asset manager, announced that they have reached an agreement for Hillhouse to acquire WuXi AppTec’s China-based clinical research services business, including WuXi Clinical, a Clinical Contract Research Organization (CRO), and WuXi MedKey, a Site Management Organization (SMO).

Strategically divesting the clinical research services business allows WuXi AppTec to further invest in and strengthen its core Contract Research, Development, and Manufacturing Organization (CRDMO) platform. This builds on the company’s legacy of exceptional drug discovery, laboratory testing, process development and manufacturing services.

“We are confident that Hillhouse’s expertise and teams will enable these businesses to reach new heights and deliver continued excellence in clinical research and site management,” said Steve Yang, Co-CEO of WuXi AppTec. “This transaction is also an important step in WuXi AppTec’s efforts to sharpen our focus on our core CRDMO strategy. Powered by our unique CRDMO platform, we are accelerating the expansion of our global capabilities and capacities to better serve our customers for the benefit of patients worldwide.”

WuXi AppTec signed a definitive agreement with Hillhouse on October 24, 2025. The transaction is subject to all mandatory government approvals/filings by all parties.